The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market. The Angelman Syndrome current treatment landscape consists of symptomatic therapy options worth USD 330.2 million in 2017. Treatment entire...
Find MoreAngelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds. The hallmarks of the syndrome constitute severe physical...
Find MoreAngelman syndrome is a rare genetic disorder, which affects the nervous system. The people who are affected by the disease, show the characteristics like intellectual disability, severe speech impairment, delayed development and issues with movement and balance. Angelman syndrome causes are due to genetic abnor...
Find MoreAI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platfo...
Find MoreALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.